VIP36

VIP36
Identifiers
  • methyl (2S)-2-{[6-[4-(diaminomethylideneamino)butoxy]-1-[(4-fluorophenyl)methyl]indazole-3-carbonyl]amino}-3,3-dimethylbutanoate
PubChem CID
Chemical and physical data
FormulaC27H35FN6O4
Molar mass526.613 g·mol−1
3D model (JSmol)
  • CC(C)(C)[C@@H](C(=O)OC)NC(=O)C1=NN(C2=C1C=CC(=C2)OCCCCN=C(N)N)CC3=CC=C(C=C3)F
  • InChI=1S/C27H35FN6O4/c1-27(2,3)23(25(36)37-4)32-24(35)22-20-12-11-19(38-14-6-5-13-31-26(29)30)15-21(20)34(33-22)16-17-7-9-18(28)10-8-17/h7-12,15,23H,5-6,13-14,16H2,1-4H3,(H,32,35)(H4,29,30,31)/t23-/m1/s1
  • Key:WMOAPWVQPPIAFY-HSZRJFAPSA-N

VIP36 is a synthetic cannabinoid derivative, closely related to the highly potent and toxic designer drug MDMB-FUBINACA. However, unlike MDMB-FUBINACA, VIP36 has been substituted with a positively charged guanidine group which prevents it from crossing the blood-brain barrier. As a result, VIP36 is highly peripherally selective and while it produces analgesic effects in animal studies, centrally mediated side effects only became evident at a 100x higher dose.[1][2]

See also

References

  1. ^ Rangari VA, O'Brien ES, Powers AS, Slivicki RA, Bertels Z, Appourchaux K, et al. (April 2025). "A cryptic pocket in CB1 drives peripheral and functional selectivity". Nature. 640 (8057): 265–273. Bibcode:2025Natur.640..265R. doi:10.1038/s41586-025-08618-7. PMC 11977287. PMID 40044849.
  2. ^ Greig IR, Ross RA (April 2025). "Designer cannabinoids could be the key to pain relief without adverse effects". Nature. 640 (8057): 45–46. Bibcode:2025Natur.640...45G. doi:10.1038/d41586-025-00546-w. PMID 40045120.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.